Durvalumab + Radiation Therapy for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

+9 other locations

Overseen byEileen M O'Reilly, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes.

Eligibility Criteria

Adults over 18 with pancreatic cancer that's locally advanced or borderline resectable, who've had FOLFIRINOX chemotherapy for 3-6 months without disease progression. They must have good organ function and not be pregnant or breastfeeding. Men and women must agree to contraception, and no recent other cancers or treatments outside the protocol are allowed.

Inclusion Criteria

I have been diagnosed with a type of pancreatic cancer that is locally advanced or borderline resectable.

Hemoglobin ≥ 9 g/dL

AST(SGOT) and ALT(SGPT) ≤ 2.5 X ULN

+17 more

Exclusion Criteria

I do not have any severe illnesses that could interfere with the study.

Patients who are currently receiving any other investigational agents for therapeutic treatment of their primary cancer.

I may have significant nerve pain or damage, subject to my doctor's approval.

+24 more

Participant Groups

The trial is testing if durvalumab combined with SABR (a type of targeted radiation therapy) is effective in treating pancreatic cancer. Durvalumab is an immunotherapy drug designed to help the immune system attack cancer cells.

1Treatment groups

Experimental Treatment

Group I: Durvalumab + SABRExperimental Treatment2 Interventions

Durvalumab + Stereotactic Ablative Body Radiotherapy

Durvalumab is already approved in European Union, United States, Japan for the following indications:

🇪🇺 Approved in European Union as Imfinzi for: